Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae, 14 April 2016
Carbapenem-resistant Enterobacteriaceae (CRE) pose a significant threat to patients and healthcare systems in all EU/EEA Member States. CRE infections are associated with high mortality, primarily due to delays in treatment and the limited availability of effective treatment options. New antibiotics which could replace carbapenems are not in sight.
This rapid risk assessment provides several options to reduce the risk of CRE, e.g. treatment options, transmission prevention and measures related to the healthcare system.
The rapid spread of carbapenem-resistant Enterobacteriaceae (CRE) poses a significant threat to patients and healthcare systems in all EU/EEA Member States.
CRE infections are associated with high mortality, primarily due to delays in administration of effective treatment and the limited availability of effective treatment options. New antibiotics capable of replacing carbapenems, a last-line group of antibiotics used to treat patients infected with multidrug-resistant bacteria, are not likely to become available in the near future. Furthermore, CRE are adapted to spread in healthcare settings as well as in the community.
This ECDC risk assessment outlines the current and possible future risks for human health, the potential for spread both in healthcare settings and in the community, and cross-border aspects that must be taken into consideration both in EU/EEA Member States and in third countries. Options for action addressing these areas are presented in the risk assessment.
Options to prevent transmission of CRE in hospitals and other healthcare settings include: timely and appropriate laboratory investigation to avoid delay in appropriate treatment, good standard infection control practices, screening of patients considered at high risk of digestive tract carriage of CRE, enhanced control measures in healthcare settings (contact precautions, patient isolation or cohorting, and dedicated nursing) for patients who are CRE-positive, and the development of antimicrobial stewardship programmes.
Rapid risk assessment: Regional outbreak of New Delhi metallo-betalactamase-producing carbapenem-resistant Enterobacteriaceae, Italy, 2018–2019
4 Jun 2019 - A large outbreak of New Delhi metallo-beta-lactamase (NDM)-producing carbapenem-resistant Enterobacteriaceae (CRE) has been reported from the Tuscany region in Italy. Between November 2018 and May 2019, seven Tuscan hospitals notified a total of 350 cases.
Rapid risk assessment: Carbapenemase-producing (OXA-48) Klebsiella pneumoniae ST392 in travellers previously hospitalised in Gran Canaria, Spain
11 Jul 2018 - This rapid risk assessment evaluates the risk of transmission and further spread of OXA-48-producing Klebsiella pneumonia e ST392 from travellers having sought medical care in Gran Canaria to healthcare facilities in their country of origin in the EU/EEA.
Rapid risk assessment: Emergence of resistance to ceftazidime-avibactam in carbapenem-resistant Enterobacteriaceae
13 Jun 2018 - This risk assessment will discuss CAZ-AVI resistance in brief, review the recent literature reporting resistance of CRE to CAZ-AVI, and assess the risk for the EU/EEA countries.